Medicare Advantage Denial Rates 2026: The Appeals Economy Reshaping Revenue Cycle Strategy

Here is the number that should stop any CFO mid-sentence: when enrollees appealed prior authorization denials for skilled nursing facility admissions issued by naviHealth, a UnitedHealth Group subsidiary, Medicare Advantage organizations overturned 97 percent of those denials. Not a majority. Not most. Virtually all of them.

At that overturn rate, the initial denial works less like a clinical determination and more like an administrative filter. It generates friction, delays care, and returns revenue only to the providers and patients with the resources to push back.

For CFOs, revenue cycle directors, and ASC board members whose income depends on fee-for-service reimbursement, the implications run deeper than one contractor's performance. They reflect a structural reality now drawing federal scrutiny, state legislative action, and a proposed CMS rule that extends prior authorization reform into prescription drugs for the first time.

The Scale of the Problem, in Hard Numbers

Medicare Advantage insurers made 52.8 million prior authorization determinations in 2024, denying 4.1 million, or 7.7%, of requests. Only 11.5% of those denied requests were appealed. But when an appeal was filed, 80.7% were overturned.

Read that sequence carefully. The vast majority of denied patients never appeal. Of those who do, more than four out of five win. The revenue that never comes back belongs to patients who absorbed the denial as final.

For post-acute and surgical providers, the numbers are more acute. A 2026 HHS Office of Inspector General report examining 19 Medicare Advantage organizations found that the three largest by enrollment denied prior authorization requests for long-term acute care hospitals and inpatient rehabilitation facilities at higher rates than most of their peers. When enrollees appealed, MAOs collectively overturned 36 percent of LTCH denials and 43 percent of IRF denials. IRF overturn rates ranged by MAO from 14 percent to 86 percent, a spread so wide it defies any explanation rooted in consistent clinical criteria.

The OIG's own investigators concluded that these findings warrant further scrutiny from CMS.

Mike Marks, CFO of HCA Healthcare, put it plainly on the company's Q1 2026 earnings call: denial and underpayment activity is "still really high," even after years of added resources, technology, and targeted payer partnerships.

The administrative cost is not theoretical. The health care industry spent roughly $1.3 billion on administrative costs tied to prior authorization in 2023, a 30 percent increase over the prior year, according to the Council for Affordable Quality Healthcare.

What Clinicians and Revenue Leaders Are Saying

The AMA's 2024 physician survey found that 29% of physicians said prior authorization had led to a serious adverse event for a patient in their care, and practices reported completing an average of 39 prior authorizations per physician per week. That volume is not absorbed by back-office staff alone. It pulls clinicians, surgeons, and specialty physicians into administrative loops that displace billable time.

The Massachusetts Division of Insurance framed the clinical stakes directly in announcing new state regulations: delayed care is inaccessible care, and inaccessible care means sicker patients, worse outcomes, and higher costs.

On revenue cycle forums and leadership calls, the frustration is consistent: the denial volume is manageable in isolation, but the cumulative drag on cash flow and staffing capacity is not. Providers who have invested in payer relations and denial management infrastructure report that the volume keeps rising faster than their capacity to absorb it.

The Policy Landscape Is Shifting, But Unevenly

Two federal developments and one state development are redefining the prior authorization environment for 2026 and beyond.

In April 2026, CMS released a proposed rule extending prior authorization interoperability mandates to prescription drugs for the first time, covering drugs under both medical and pharmacy benefits. The proposed rule requires electronic prior authorization, shorter decision timelines, more specific denial explanations, and standardized data exchange. The public comment deadline was June 15, 2026.

An AJMC analysis characterizes this not as administrative streamlining but as a systemic redesign of how prior authorization functions across CMS programs. For providers with significant drug-adjacent revenue, including oncology, infusion, and surgical pharmacology, the proposed rule changes the documentation and workflow calculus.

At the state level, Massachusetts moved further and faster than federal policy. New regulations that took effect June 5, 2026 eliminated prior authorization requirements for cancer scans, chronic disease medications, emergency and urgent care, maternity care, outpatient substance use disorder treatment, physical and occupational therapy, and medications for serious mental illness. For providers in that market, this is immediate revenue cycle relief. For providers in other states watching the precedent, it signals where regulatory pressure is building.

The contractor accountability gap highlighted in the OIG's naviHealth findings is unlikely to be resolved by the proposed CMS rule alone. naviHealth processed half of all SNF admission requests and denied 14 percent of them, a higher denial rate than MAOs that processed requests internally at 11 percent, and other contractors at 9 percent. The OIG report specifically raises concerns about whether contractors are receiving appropriate training and oversight from MAOs.

For post-acute providers and surgical networks, the contractor identity behind a denial now matters as much as the denial category itself.

What Revenue Cycle Leaders Should Do Before Q4

The policy and enforcement environment in 2026 creates specific leverage points. Here is where to focus.

1. Segment your denial data by contractor, not just by payer. The OIG data shows overturn rates varying by MAO from 14 percent to 86 percent for IRF denials. If your team treats all United or Humana denials as equivalent, you are missing the contractor-level patterns that predict appealability. Identify which contractors generate the highest overturn rates and resource your appeals workflow accordingly.
2. Stop treating the appeal as a last resort. An 80.7% overturn rate on appealed prior authorization denials means the appeal is frequently the correct first response, not a fallback. Revenue cycle directors should audit whether their teams appeal at a rate that reflects the actual win probability, rather than a rate shaped by historical reluctance or staffing constraints.
3. Map your drug-adjacent service lines against the proposed CMS rule. The April 2026 proposed rule is in comment period, but the direction is clear. Practices and systems with infusion, oncology, or specialty pharmacy revenue should begin internal assessments of how electronic prior authorization requirements and shorter decision timelines will affect existing workflows. Waiting for a final rule to begin costs implementation runway.
4. Track state-level prior authorization reform in your operating markets. Massachusetts set a June 2026 effective date for broad elimination. Several other states have active legislation in similar territory. Revenue cycle leaders managing multi-state footprints need a monitoring function that translates regulatory changes into payer contract and workflow implications, not just compliance checklists.
5. Audit nursing home and post-acute referral denials. The OIG found that MAOs and their contractors denied requests for SNF-level care from nursing home residents 40 percent of the time, compared to 11 percent for all other enrollees. That signals a population being denied at a rate that is both clinically indefensible and legally exposed. Providers in this space should document medical necessity contemporaneously and build appeal infrastructure specific to this denial category.

When a contractor overturns 97% of its own denials on appeal, the initial denial has stopped functioning as clinical gatekeeping. It has become a cash flow mechanism that works only on the patients and providers who do not push back. Federal watchdogs have now documented this in writing, and the regulatory response is accelerating at both the federal and state levels. Revenue cycle leaders who restructure their denial management strategy around actual overturn probability, rather than historical deference to payer determinations, will recover revenue that is currently being left on the table by design.